BioGrad’s significant £3m investment signifies its expanding footprint across the UK.
- BioGrad has announced the opening of a new research and teaching site in York.
- The company plans to launch a nationwide clinical trial led by the York team in early 2025.
- BioGrad’s expansion aligns with its strategy to lead in science and healthcare research.
- Local authorities and councils have been instrumental in facilitating BioGrad’s York expansion.
Laboratory technology firm BioGrad has made a noteworthy move by investing £3m to establish a new facility in Yorkshire as part of its ongoing national expansion strategy. The Liverpool-based company’s new research and teaching site in York is set to enhance its presence, placing BioGrad at the forefront of science and healthcare, particularly focusing on regenerative medicine and clinical research over the coming three years.
The company is gearing up for a significant milestone with plans to announce a nationwide clinical trial, spearheaded by the newly formed York team, slated for early 2025. This initiative signifies BioGrad’s commitment to advancing clinical research and underscores the strategic importance of its Yorkshire expansion.
Since 2022, BioGrad has rapidly expanded its operations by opening laboratories in major locations including Birmingham, Newcastle, and London. It has also developed a purpose-built clinical research centre in Liverpool, which serves as its headquarters. The company’s growth trajectory was further strengthened when BioGrad Education became the first North West company to secure investment from the £660m Northern Powerhouse Investment Fund II.
Dr Natalie Kenny, CEO of BioGrad, highlighted the significance of the expansion, expressing enthusiasm about the new era for BioGrad facilitated by expansion across the UK. She acknowledged the vital support received from local entities, including York and North Yorkshire Combined Authority and key individuals such as Sophie Hartley and Christine Hogan, in choosing York for this expansion.
York’s regional strengths, including its world-class NHS Trust and esteemed universities, have been pivotal in attracting BioGrad to the city, promising the creation of quality, skilled jobs in a burgeoning sector. Dr Kenny emphasized BioGrad’s pride in its UK-wide presence and its continuous efforts to foster job creation and opportunities across the region.
David Skaith, Mayor of York and North Yorkshire, expressed his optimism about BioGrad’s investment, which promises more than £3 million over the next three years. He noted that the demographic and institutional strengths of York reinforce the city’s position as a significant player in global healthcare.
BioGrad’s strategic expansion into York marks a promising advancement in the scientific and healthcare research sectors.
